Meta Pixel

News and Announcements

Emergence 2022: Capital Raising Insights From Jason Calacanis

  • Published December 20, 2022 12:37AM UTC
  • Publisher Leila Oliveira
  • Categories Capital Raising Tips

3 insights from Jason Calacanis at Emergence 2022:

๐•๐š๐ฅ๐ฎ๐š๐ญ๐ข๐จ๐ง

15 years a series A round would be around 3-5M dollars. Now we see seed rounds raising this amount with no governance, no lead investor and thatโ€™s a recipe for disaster as the company will suffer when the market corrects. He calls it the valuation trap.

“Iโ€™m not saying to ask for a lower valuation, but founders, investors and board members should be aware of the risks of a wrong valuation. Those crazy high valuations weโ€™ve seen during COVID, theyโ€™re gone. such as Snowflake, Peloton, Doordash.”

๐–๐ก๐š๐ญ ๐ฌ๐ž๐œ๐ญ๐จ๐ซ ๐ž๐ฑ๐œ๐ข๐ญ๐ž๐ฌ ๐ฒ๐จ๐ฎ ๐ญ๐ก๐ž ๐ฆ๐จ๐ฌ๐ญ?

His excitement is not dependent on the sector but on the founder; However, he mentions:

โ–ช๏ธ FinTech

โ–ช๏ธ Marketplace

โ–ช๏ธ SaaS

โ–ช๏ธ Consumer software and consumer subscriptions

๐–๐ก๐š๐ญ ๐š๐ซ๐ž ๐ญ๐ก๐ž ๐ฆ๐จ๐ฌ๐ญ ๐ข๐ฆ๐ฉ๐จ๐ซ๐ญ๐š๐ง๐ญ ๐ช๐ฎ๐š๐ฅ๐ข๐ญ๐ข๐ž๐ฌ ๐ฒ๐จ๐ฎ ๐ฅ๐จ๐จ๐ค ๐Ÿ๐จ๐ซ ๐ข๐ง ๐š ๐Ÿ๐จ๐ฎ๐ง๐๐ž๐ซ?

High energy, resilience and grit.

Grit alone isnโ€™t enough. You need to be able to recruit and build a great product.

๐Ÿ“ He also shared his thoughts on the blockchain, web3 and strategic investors.

Would you like part 2 with these topics?

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimericโ€™s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patientโ€™s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “Itโ€™s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now